DARA BioSciences to Present DB959 At the 'Annual Targeting Diabetes with Novel Therapeutics' Meeting Sponsored by Cambridge Healthtech Institute
May 14, 2009 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 14, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the DB959 program has been identified by Cambridge Healthtech Institute ("CHI") for inclusion...
DARA BioSciences Announces Positive Trial Results of KRN5500 for Treatment of Neuropathic Pain in Patients With Cancer
May 12, 2009 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., May 12, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced positive results from a Phase 2a clinical trial of KRN5500 for treatment of neuropathic pain in...
DARA BioSciences Appoints Gail F. Lieberman to Its Board of Directors
April 30, 2009 13:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 30, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced the appointment of Gail F. Lieberman to its Board of Directors. The appointment was effective April 27,...
DARA BioSciences, Inc. Announces Going Concern and NASDAQ Notice
April 10, 2009 17:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., April 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA) ("DARA" or the "Company"), a development-stage pharmaceutical company, announced today that the audit report...
DARA BioSciences to Present Abstracts for DB959 At American Diabetes Association Scientific Sessions
March 30, 2009 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 30, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that two abstracts have been accepted for presentation at the annual American Diabetes...
United States Food and Drug Administration ('FDA') Approves DARA Investigational New Drug Application ('IND') for DB959 -- An Oral Medication Intended for the Treatment of Type 2 Diabetes
March 10, 2009 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), today announced that the United States Food and Drug Administration ("FDA") has cleared the Company's...
DARA Raises $1,000,000 in New Capital
February 05, 2009 07:45 ET
|
DARA BioSciences, Inc.
Richard A. Franco, Sr. Appointed as Chief Executive Officer and Director
DARA Files Investigational New Drug Application ("IND") With the United
States Food and Drug Administration...
DARA BioSciences Raises $2,255,000 Through the Sale of Common Stock and Warrants
October 21, 2008 17:58 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 21, 2008 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company focused on compounds designed to address diabetes, neuropathic pain...
DARA BioSciences Announces Completion of Toxicology Studies for Its PPAR-delta/gamma Agonist, DB959
October 02, 2008 09:18 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 2, 2008 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, announced the completion of all toxicology studies necessary for...
DARA BioSciences Plans to Restate Financial Statements for the Quarter Ended March 31, 2008 to Reflect Increased Valuation of Investment
August 14, 2008 18:22 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Aug. 14, 2008 (PRIME NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) reported today that it expects to restate its financial statements for the quarter ended March 31, 2008, to...